A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma

NCT02707666 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

7

Enrollment

OTHER

Sponsor class

Stopped unable to complete enrollment

Conditions

Pleural Mesothelioma

Interventions

DRUG: Pembrolizumab
DRUG: Cisplatin and Pemetrexed

Sponsor

University of Chicago